|
FDA stamps approval on Hyperion's new orphan drug
FierceBiotech Hyperion ($HTPX) has won its first FDA approval. The South San Francisco-based company grabbed the agency's nod for its drug Ravicti, a treatment for managing genetic conditions known as urea cyclic disorders. The approval comes after U.S. regulators … |
More: continued here
